9.3 Pediatric Overweight & Obesity (AAP 2023 Guideline)
Key Takeaways
- Overweight is BMI ≥85th to <95th percentile; obesity is ≥95th percentile; severe obesity is ≥120% of the 95th percentile or BMI ≥35, whichever is lower.
- Intensive Health Behavior and Lifestyle Treatment (IHBLT) — at least 26 contact hours of face-to-face, family-based, multicomponent treatment over 3–12 months — is the most effective known treatment.
- Expectant management ('watchful waiting') is NOT appropriate; the AAP 2023 guideline directs early evaluation and treatment at the highest intensity available.
- Pharmacotherapy is an adjunct to lifestyle treatment from age 12 years — semaglutide and liraglutide are approved ≥12 yr, phentermine short-term ≥16 yr, orlistat ≥12 yr.
- Refer adolescents ≥13 years with severe obesity (BMI ≥120% of the 95th percentile with comorbidity, or ≥140%) for metabolic and bariatric surgery evaluation.
Definitions
Pediatric weight status is defined by BMI percentile for age and sex (CDC growth charts, ages 2–19):
| Category | Definition |
|---|---|
| Overweight | BMI ≥85th to <95th percentile |
| Obesity | BMI ≥95th percentile |
| Severe obesity | BMI ≥120% of the 95th percentile or BMI ≥35, whichever is lower |
| Extreme (class 3) obesity | BMI ≥140% of the 95th percentile or BMI ≥40 |
BMI ≥95th percentile now affects roughly 1 in 5 US children and adolescents. Below age 2, weight-for-length above the 97.7th percentile on WHO charts flags excess adiposity.
Comorbidity Screening
Obesity in youth is a multisystem disease. Recommended evaluation includes:
- Dyslipidemia: fasting or non-fasting lipid panel
- Hepatic: ALT to screen for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD)
- Glycemic: fasting glucose and/or HbA1c for prediabetes and type 2 diabetes
- Blood pressure with a properly sized cuff at every visit
- Obstructive sleep apnea: history and validated screening
- PCOS in adolescent girls with irregular menses or hyperandrogenism
- Orthopedic: slipped capital femoral epiphysis (SCFE), Blount disease
- Mental health: depression, anxiety, binge eating, bullying, and weight stigma
Physical findings worth naming on the exam include acanthosis nigricans (a marker of insulin resistance), hepatomegaly with steatotic liver disease, hip or knee pain suggesting SCFE, and tonsillar hypertrophy contributing to sleep-disordered breathing. Review the full BMI trajectory rather than a single point, and ask about rapid gain triggers such as new medications (atypical antipsychotics, glucocorticoids), reduced activity after injury, or family transitions. Before prescribing any weight intervention, screen for disordered eating — rigid dieting, binge eating, and purging can co-exist with obesity, and an inappropriate restrictive prescription can worsen them.
AAP 2023 Clinical Practice Guideline: Core Principles
The American Academy of Pediatrics (AAP) 2023 Clinical Practice Guideline treats obesity as a chronic disease requiring longitudinal care. Its pivotal messages:
- Expectant management — 'watchful waiting' — is NOT appropriate. Evaluate comorbidities and offer treatment early and at the highest intensity available, rather than waiting for the child to 'grow out of it.'
- Intensive Health Behavior and Lifestyle Treatment (IHBLT) is the most effective known treatment: at least 26 contact hours of face-to-face, family-based, multicomponent treatment (nutrition, physical activity, behavior change) delivered over 3–12 months. Programs with fewer contact hours produce little durable effect — the dose-response relationship is a favorite exam point. IHBLT remains under-available, so clinicians should refer whenever it exists and approximate it when it does not.
- Motivational interviewing is the recommended communication style — patient-centered, autonomy-supportive, non-judgmental.
- Young children: for 2–5 year olds with obesity, weight loss is generally not needed; the goal is decelerating BMI velocity and establishing healthy behaviors while growth in height normalizes the trajectory.
Pharmacotherapy (Adjunct to Lifestyle Treatment)
Medication is offered as an adjunct — never a replacement — for health behavior and lifestyle treatment, for youth ≥12 years with obesity:
| Agent | Age | Notes |
|---|---|---|
| Semaglutide 2.4 mg weekly | ≥12 yr | GLP-1 receptor agonist; largest mean BMI reduction of approved agents |
| Liraglutide 3.0 mg daily | ≥12 yr | GLP-1 receptor agonist |
| Phentermine | ≥16 yr | Short-term (up to 12 weeks) sympathomimetic |
| Orlistat | ≥12 yr | Lipase inhibitor; GI side effects; supplement fat-soluble vitamins |
| Setmelanotide | ≥6 yr | Only for rare monogenic/syndromic obesity (e.g., POMC, LEPR deficiency, Bardet-Biedl) |
GLP-1 receptor agonists most commonly cause transient nausea, vomiting, and constipation; counsel families on gradual dose titration, hydration, and smaller meals, and reinforce that discontinuation typically leads to weight regain, underscoring the chronic-disease model. Co-prescribe or intensify behavioral treatment rather than presenting medication as a stand-alone fix, and set realistic expectations: agents are tools to make lifestyle change achievable, not cures.
Behavioral Strategies and Activity Targets
Core behavioral techniques used in IHBLT include self-monitoring (food and activity logs), specific measurable goal setting, stimulus control (keeping energy-dense foods out of the home, designated eating locations), positive reinforcement that rewards behaviors rather than the scale, and parent modeling — family-based means the caregivers change alongside the child. Physical activity guidance mirrors general pediatric recommendations: at least 60 minutes of moderate-to-vigorous activity daily, plus limiting sedentary time. The dietitian individualizes an eating pattern emphasizing vegetables, fruits, whole grains, lean protein, and minimally processed foods without prescribing rigid calorie restriction in growing children.
Metabolic & Bariatric Surgery
Refer adolescents ≥13 years with severe obesity — BMI ≥120% of the 95th percentile with a clinically significant comorbidity, or ≥140% of the 95th percentile — to a multidisciplinary bariatric surgery center for evaluation. Sleeve gastrectomy is the most common procedure; adolescent data (Teen-LABS) show durable weight loss of roughly 25–30% and high remission rates of type 2 diabetes and hypertension, alongside needs for lifelong micronutrient monitoring.
Environment, Policy, and Stigma
Counsel on eliminating or sharply reducing sugar-sweetened beverages (the single most modifiable dietary target), limiting recreational screen time with a family media plan, and ensuring adequate sleep (insufficient sleep is independently associated with obesity). Use person-first, non-stigmatizing language ('child with obesity,' never 'obese child') — weight stigma worsens outcomes, promotes avoidance of care, and fuels disordered eating. The registered dietitian partners with primary care to deliver intensive, family-based behavioral treatment and to monitor growth without promoting restrictive dieting.
A 15-year-old has a BMI of 38, which is 130% of the 95th percentile for age and sex. How is this classified?
According to the AAP 2023 guideline, Intensive Health Behavior and Lifestyle Treatment (IHBLT) is defined by which minimum treatment dose?
Which adolescent meets the AAP 2023 referral criteria for metabolic and bariatric surgery evaluation?